Prazosin and cyproheptadine in combination in the treatment of alcohol use disorder: A randomized, double-blind, placebo-controlled trial.

Date publication

avril 2024

Journal

Addiction (Abingdon, England)

Auteurs

Membres identifiés du Cancéropôle Est :
Pr TROJAK Benoît

Tous les auteurs :
Aubin HJ, Berlin I, Guiraud J, Bruhwyler J, Batel P, Perney P, Trojak B, Bendimerad P, Guillou M, Bisch M, Grall-Bronnec M, Labarrière D, Delsart D, Questel F, Moirand R, Bernard P, Trovero F, Pham HP, Tassin JP, Puech A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/38597214

Résumé

Pre-clinical studies suggest that the simultaneous blockade of the α1b and 5HT2A receptors may be effective in reducing alcohol consumption. This study aimed to assess the efficacy and safety of prazosin (α1b blocker) and cyproheptadine (5HT2A blocker) combination in decreasing total alcohol consumption (TAC) in alcohol use disorder (AUD).

Mots clés

Alcohol reduction, alcohol use disorder, cyproheptadine, prazosin, randomized controlled trial, risk drinking level

Référence

Addiction. 2024 04 10;: